News

A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.

New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.

A new study found an intervention targeting proton pump inhibitor overuse was linked to an absolute reduction of 7.3%.

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

A recent study found Black individuals had a sharp increase in midlife deaths from suicide, drug overdose, and alcoholic liver disease after 2015.

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.

Vision issues were linked to an increased risk of suicidal ideation, suicidal behavior, and suicide death, particularly among adolescents.

In this analysis, investigators sought to assess PsA development probability in subclinical PsA as well as to characterize symptoms and patterns of subclinical PsA.

This analysis looked at the potential connection between SARS-CoV-2 test positivity and new asthma diagnoses.

In an interview with HCPLive, Rishi Kakar, MD, discussed the positive long-term xanomeline-trospium data from EMERGENT-4.

Topline data from the SURMOUNT-OSA studies provide insight into the effects of tirzepatide in OSA with obesity, with Lilly disclosing plans for a regulatory submission mid-year.

Incident use of anti-TNF therapy was linked to an increased risk of kidney function decline but not all-cause mortality in patients with newly diagnosed IBD.

The FDA approved ustekinumab-aekn for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.

Mendelian randomization analysis demonstrated a direct connection between rheumatoid arthritis and an increased risk of age-related macular degeneration.

Fresenius announced the immediate availability of its tocilizumab biosimilar, tocilizumab-aazg (Tyenne), in the US.

A proactive treat-and-extend protocol yields superior results with fewer visits than a less intensive regimen in the first year of treatment for DME.

Olezarsen shows promise in managing familial chylomicronemia syndrome, reducing triglycerides and acute pancreatitis events.

A new study found individuals with PTSD face rapid transitions between neutral and negative emotional states.

Barratt discusses results from subgroup analyses of the phase 3 PROTECT trial based on baseline proteinuria and what they add to previous findings.

Ersilia DeFillipis, MD, discusses a trio of studies she presented at ACC.24 examining different financial hurdles and barriers encountered by people in need of heart transplants.

An ACC.24 analysis found a decline in TTM use post-2013 TTM trial, which investigators suggest indicates a potential misinterpretation of trial findings.

In this analysis, the study investigators highlighted the impact of smoking cigarettes on PASI 75 achievement.

A new study explored increased health care utilization of children among several specific sleep disorders, race, and age.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This edition focuses on 5 updates from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions.

Barratt discusses the potential of targeting the alternative pathway for controlling inflammation and the significance of the new APPLAUSE-IgAN data.

A recent multi-center study identified risk factors linked to premature mortality in sickle cell disease, including male gender and hematologic and biochemical parameters.

Laura Ross, PA-C, sits down for a Q&A on the HeartBeet Clinic and the role of reimbursable group visits in cardiovascular disease management and education.